<DOC>
	<DOCNO>NCT01008059</DOCNO>
	<brief_summary>To evaluate two paradigms simultaneous assessment hepatic intestinal CYP3A activity .</brief_summary>
	<brief_title>Alfentanil : Simultaneous Testing Pilot</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Alfentanil</mesh_term>
	<criteria>Male nonpregnant female , 1840 yr. old Good general health remarkable medical condition liver , kidney , heart , lung failure BMI 2033 Provide inform consent Known history liver kidney disease Use prescription non prescription medication , herbal food know metabolized affect CYP3A ( include oral birth control medication ) Females pregnant nursing Known history drug alcohol addiction ( prior present addiction treatment addiction ) Direct physical access routine handle addict drug regular course duty ( routine exclusion study drug addiction potential ) . History bradycardia Respiratory rate &lt; 10 History significant pulmonary disease History preexist medical condition predispose respiratory depression Systolic blood pressure &lt; 100 mgHg diastolic blood pressure &lt; 70mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>